Get drug firms out of drug approval

By: 

In a commentary for APM's Marketplace, Dr. Stefan Kertesz questions the current process of approving new drugs, especially when researchers who set health care guidelines also have financial interests in pharmaceutical companies. He cites the timing  of the National Cholesterol Education Panel's announcement on recommended cholesterol levels and the drug Vytorin's release to illustrate the need for reform. 

Original Article

Topic: 

Add new comment

Filtered HTML

  • Web page addresses and e-mail addresses turn into links automatically.
  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd> <p> <div> <br> <sup> <sub>
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Refresh Type the characters you see in this picture. Type the characters you see in the picture; if you can't read them, submit the form and a new image will be generated. Not case sensitive.  Switch to audio verification.